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Abstract
Objective: Both type 2 diabetes and glucocorticoid therapy are highly prevalent. Although people with
type 2 diabetes may be more susceptible to adverse effects of glucocorticoids, and it is recommended
that glucocorticoid therapy is avoided for fear of worsening glycaemic control, the extent to which this
advice is followed and the consequences when glucocorticoids are prescribed are poorly documented.
The aim was to assess the characteristics of people with type 2 diabetes prescribed glucocorticoids in a
real-world setting and to quantify resulting adverse effects.
Design: Cross-sectional cohort study.
Methods: Cardiometabolic variables, body fat distribution, cognitive function and mood were studied in
the 1066 participants of the Edinburgh Type 2 Diabetes Study, of whom 162 (15%) were taking
systemic, topical or inhaled glucocorticoids.
Results: Glucocorticoid therapy was more common in women and in smokers but was not avoided in
patients with diabetic complications or cardiovascular risk factors. People taking glucocorticoids were
more centrallyobese with slightly higher HbA1c and total serum cholesterol but were no more likely to
have hepatic steatosis or hypertension. Glucocorticoid treatment was associated with substantially
lower mood and greater anxiety. Women taking glucocorticoid therapy were twice as likely to report
depressive symptoms compared with those not taking treatment. Glucocorticoid therapy was also
associated with poorer cognitive function among those with subclinical atherosclerosis, as indicated by
low ankle–brachial pressure index.
Conclusions: Glucocorticoids are prescribed commonly for people with type 2 diabetes despite being
associated with adverse indices of glycaemic control, cardiovascular risk factors, mood and cognitive
function.
European Journal of Endocrinology 166 861–868
Introduction
Data from the UK suggest that w1% of the adult
population are prescribed oral glucocorticoids (1) and
a larger proportion receive inhaled or topical gluco-
corticoids with potential for adverse systemic effects.
It is well known that acute effects of glucocorticoids
may cause hyperglycaemia by increasing insulin
resistance (2) and inhibiting glucose-stimulated
insulin secretion from pancreatic b-cells (3). In the
medium term, glucocorticoid-induced obesity and liver
fat accumulation may exacerbate this metabolic
dysfunction. After chronic administration, the pro-
pensity of glucocorticoids to produce hyperglycaemia,
hypertension and dyslipidaemia may confer an
increased risk of myocardial infarction (MI), stroke
and heart failure (4, 5). Moreover, glucocorticoid
therapy has additional adverse effects, including on
mood (6, 7) and cognitive ability (6, 8). As people with
type 2 diabetes are at high cardiovascular risk (9), are
susceptible to depression (10) and have accelerated
cognitive decline (11), and preventing cardiovascular
disease is the major goal of anti-diabetic therapy, it
appears logical to conclude that glucocorticoid therapy
should be avoided in people with type 2 diabetes.
However, in many inﬂammatory diseases, gluco-
corticoid therapy can be difﬁcult to avoid. Although
several studies have quantiﬁed an approximately twofold
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with glucocorticoid therapy (12, 13, 14), the con-
sequences of resorting to glucocorticoid therapy in
people with established type 2 diabetes are poorly
documented. As many people with type 2 diabetes are
prescribed therapies to reduce cardiovascular risk,
including lipid- and blood pressure-lowering agents,
it is uncertain whether the adverse cardiovascular risk
associated with glucocorticoid therapy is manifest in
people with type 2 diabetes. Against this background,
we aimed to establish whether glucocorticoid therapy
is avoided in people with type 2 diabetes, in particular
those most at risk of cardiovascular disease, and
document the consequences when it is not avoided. As
it would not be ethical to conduct a randomised
controlled trial to answer these questions on gluco-
corticoid exposure, we used an observational study to
examine the adverse associations with glucocorticoid
therapy in a large well-characterised cohort of people
with type 2 diabetes, the Edinburgh Type 2 Diabetes
Study (ET2DS).
Materials and methods
Participants and procedures
The ET2DS is a prospective study investigating
mechanisms and risk factors for diabetes-related
cognitive decline and for the development and pro-
gression of micro- and macro-vascular disease in
diabetes (15). One thousand and sixty-six participants
aged 60–75 years were recruited at random from a
comprehensive database of people with type 2 diabetes
living in the Lothian region of southeast Scotland
during August 2006–2007. The recruitment and study
protocol have been described in detail previously (15).
Brieﬂy, subjects attended a local research clinic for
physical examination including anthropometry,
measurement of blood pressure, ankle–brachial index
(ABI) and recording of ECG. Subjects completed
questionnaires containing validated questions on
demographic characteristics, recall of a doctor diagnosis
of MI and angina, the WHO chest pain questionnaire
(16) and cardiovascular risk factors. Cognitive ability
was assessed using a comprehensive batteryof validated
psychometric tests, and a general cognitive ability
factor, g, was calculated as described previously (11).
The Hospital Anxiety and Depression Scale (HADS) was
used to evaluate current anxiety and depressive
symptoms. This scale performs well in screening for
the separate dimensions of anxiety and depression in
older people (17) and allows identiﬁcation of cases of
anxiety disorders and depression in patients from non-
psychiatric hospital clinics (18). A fasting blood sample
was collected for measurement of plasma glucose,
HbA1c, total and HDL-cholesterol, liver function tests
and inﬂammatory markers including white cell count,
neutrophil count, C-reactive protein (CRP), interleukin
6 (IL6) and ﬁbrinogen levels. Data were also collected
from the Information Services Division of NHS Health
Services Scotland on all medical and surgical discharges
fromScottishhospitalssince1981(SMR01scheme).Any
ICD10 or ICD9 codes for cardiovascular or cerebro-
vascular disease were extracted. Ischaemic heart disease
was deﬁned and categorised as described previously (19).
One year after baseline examination, participants
were invited to attend again for assessment of liver
structure. Nine hundred and thirty-nine subjects (88%
of the original cohort) attended after a 4-h fast for an
ultrasound of the liver (20). The results were graded for
hepatic steatosis using standardised criteria and vali-
dated with
1H magnetic resonance spectroscopy (MRS),
the non-invasive gold standard for quantiﬁcation of
hepatic fat (21). Non-alcoholic fatty liver disease was
deﬁned as the presence of deﬁnite hepatic steatosis on
ultrasound scan (i.e. Grade 3) in the absence of a
secondary cause for hepatic steatosis.
The study complied with the Declaration of Helsinki
and ethical approval and written informed consent
were obtained.
Assessment of glucocorticoid exposure
Subjects were asked whether they had taken glucocor-
ticoid therapy by any route (oral, inhaled, i.m. or
topical) within the last 3 months. These data were
veriﬁed by manually checking through primary care
records to conﬁrm that a prescription was given.
Statistical analysis
Data were analysed using SPSS 17.0(SPSS Inc.,
Chicago, IL, USA). The primary analyses compared all
subjects exposed to glucocorticoids by any route. Only
when the primary analysis showed a statistically
signiﬁcant difference, a secondary analysis was per-
formed to examine dose–response relationships by
comparing those receiving glucocorticoids by topical,
inhaled or systemic (oral or i.m.) routes. As there were
only two subjects taking i.m. glucocorticoids, we
grouped oral and i.m. glucocorticoids in the same
category (equivalent to high-dose, systemic therapy).
Differences in characteristics, diabetic complications,
metabolic proﬁle and performance on the cognitive tests
between those taking glucocorticoid treatment or not
takingglucocorticoids were tested using unpaired t-tests
or c
2 tests as appropriate. Multivariate analysis with
general linear modelling (analysis of covariance
(ANCOVA)) was performed including potential con-
founding factors of duration of diabetes, other therapies
(e.g. for diabetes or lipid lowering), smoking and body
mass index (BMI) as covariables as indicated. A trend
analysis examining the dose–response relationship
among treatment groups (not taking glucocorticoids,
topical, inhaled and systemic) was performed using
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adjust cognitive measures by several covariates includ-
ing Mill Hill Vocabulary Scale, which was used as an
indicator of peak prior ability and thereby afforded the
estimation of lifetime cognitive change. As the distri-
bution of several variables (Trail Making Test, HADS
anxiety and depression score, g-glutamyl transferase,
CRP, IL6) was skewed, we used natural log transfor-
mation to normalise these variables. To test for gender
differences in depression and anxiety scores, a stratiﬁed
analysis by gender was performed. The depression
scores were also categorised using a score of R8 and
odds ratios (OR) for risk of depression according to
glucocorticoid therapy calculated.
Based on our previous observation of a signiﬁcant
interaction between circulating cortisol levels and
subclinical atherosclerosis (as measured by ABI) in
predicting cognitive dysfunction in subjects with type
2 diabetes (11), we tested the interaction between
ABI and glucocorticoid treatment in all ANCOVA
analyses related to mood and cognitive measures.
A stratiﬁed analysis by ABI (!0.8 vs R0.8) was
carried out to test whether glucocorticoid treatment
was associated with poorer cognitive performance in
those with lower ABIs.
Logistic regression was used to adjust dichotomous
variables (e.g. hepatic steatosis) for potential confound-
ing factors. Glucocorticoid treatment and other
covariates were included in the equation as independent
variables with the enter method.
Results
Characteristics of participants treated with
glucocorticoids
One hundred and sixty-two (15%) of the subjects had
taken glucocorticoid treatment within the 3 months
before the study. Of these, 12% were taking topical
glucocorticoids, 70% inhaled glucocorticoids and 23%
oral glucocorticoids. Six per cent were taking a com-
bination of two forms of glucocorticoid therapy and two
participants had received i.m. injections. Treatment was
mostcommonlyprescribedforlungconditions(77%),skin
conditions (30%), polymyalgia rheumatica or arthritis
(14%)andgastrointestinalconditions(2%).Table 1 shows
that those taking glucocorticoids were more likely to be
female and to be current smokers. Table 2 shows that
subjects taking glucocorticoid therapy had a worse
inﬂammatory proﬁle with signiﬁcantly higher white
blood cell count, neutrophil count, CRP and IL6 levels.
However,therewerenosigniﬁcantdifferencesinlikelihood
of prescription of glucocorticoid therapy according to
current therapies for diabetes, associated cardiovascular
risk factors or current diabetic complications.
Table 1 Characteristics of participants. Data are mean (S.D.) or n (%).
Not taking
GCs (nZ904)
Taking GCs
(nZ162)
Topical
(nZ15)
Inhaled
(nZ107)
Oral/i.m.
(nZ40)
GCs vs non-GCs
P value
a (P value
for trend analysis
b)
Female gender 428 (47.3) 91 (56.2) 8 (53.3) 60 (56.1) 23 (57.5) 0.038 (0.039)
Age at assessment (years) 67.9 (4.2) 68.1 (4.1) 66.7 (3.4) 67.7 (4.1) 69.9 (4.0) 0.510
Smoking status
Current smoker 118 (13.1) 30 (18.5) 8 (53.3) 32 (29.9) 17 (42.5) 0.155
Ex-smoker 426 (47.1) 75 (46.3) 5 (33.3) 55 (51.4) 15 (37.5)
Never smoked 360 (39.8) 57 (35.2) 2 (13.3) 20 (18.7) 8 (20)
Duration of diabetes (years) 9.1 (6.5) 8.7 (5.9) 6.6 (4.2) 9.3 (6.6) 8.0 (4.3) 0.449
Treatment of diabetes
Diet alone 169 (18.7) 32 (19.8) 2 (13.3) 23 (21.5) 7 (17.5) 0.865
Oral hypoglycaemic agents 578 (63.9) 100 (61.7) 12 (80) 63 (58.9) 25 (62.5)
InsulinGoral hypoglycaemic agents 157 (17.4) 30 (18.5) 1 (6.7) 21 (19.6) 8 (20)
Lifetime history of severe hypoglycaemic
episodes (one or more episodes)
84 (9.5) 21 (13.2) 2 (13.3) 14 (13.3) 5 (12.8) 0.154
Treated hypertension 712 (78.8) 131 (81.4) 13 (86.7) 84 (79.2) 34 (85.0) 0.453
Treated dyslipidaemia 764 (84.5) 133 (82.1) 13 (86.7) 87 (81.3) 33 (82.5) 0.438
Occlusive vascular disease
Myocardial infarction 123 (13.6) 27 (16.7) 3 (20) 14 (13.1) 10 (25) 0.302
Angina 245 (27.1) 53 (32.7) 7 (46.7) 35 (32.7) 11 (27.5) 0.143
Cerebrovascular disease (stroke or TIA) 80 (8.8) 13 (8) 1 (6.7) 10 (9.3) 2 (5.0) 0.732
Ankle–brachial index 0.98 (0.21) 0.97 (0.19) 0.99 (0.11) 0.95 (0.20) 1.01 (0.19) 0.443
Neuropathy
Vibration threshold right foot (V) 14.7 (8.9) 14.6 (9.2) 13.0 (9.6) 14.3 (8.9) 16.0 (9.8) 0.914
Vibration threshold left foot (V) 15.0 (9.1) 14.1 (9.3) 15.1 (10.7) 13.6 (8.7) 15.1 (10.3) 0.294
Albumin/creatinine ratio (mg/mmol) 4.9 (10.0) 6.6 (16.1) 1.4 (1.4) 5.4 (12.1) 11.0 (25.3) 0.244
GCs, glucocorticoids; TIA, transient ischaemic attack.
aT-test and c
2 test were used to compare continuous or categorical variables between treatment groups (GCs vs non-GCs).
bTrend analysis was performed when primary analyses using T-test or c
2 tests were signiﬁcant. Four groups were considered for this analysis: i) not taking
GCs, ii) topical, iii) inhaled and iv) oral/i.m. For continuous variables, the linear polynomial contrast of the ANOVA was used.
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proﬁle
Table 2 shows that subjects taking glucocorticoids had
higher BMI and waist:hip ratios than those on no
treatment. Glucocorticoid treatment was also associated
with poorer glycaemic control, as demonstrated by a
trend for higher HbA1C that became signiﬁcant in
multivariate analysis. Total serum cholesterol and also
HDL-cholesterol were higher in those taking glucocorti-
coid treatment; these ﬁndings remained signiﬁcant after
adjustment for lipid-lowering therapy. Blood pressure
did not differ according to glucocorticoid therapy, even
after adjustment for anti-hypertensive therapy. The
prevalence of severe hepatic steatosis on ultrasound
tended to be higher in participants receiving
Table 2 Metabolic and anthropometric variables. Data are mean (S.D.), n (%) or median (interquartile range).
GCs vs non-GCs
Not taking
GCs (nZ904)
Taking GCs
(nZ162)
Topical
(nZ15)
Inhaled
(nZ107)
Oral/i.m.
(nZ40)
Unadjusted
P value
a
Adjusted P value
b
(adjusted P value
for trend
c)
Metabolic variables
Fasting plasma glucose
(mmol/l)
7.6 (2.1) 7.5 (2.2) 7.6 (2.0) 7.8 (2.3) 6.8 (1.7) 0.702 0.842
HbA1c (%) 7.4 (1.1) 7.5 (1.4) 7.3 (0.8) 7.5 (1.4) 7.7 (1.4) 0.079 0.043 (0.115)
Systolic blood pressure
(mmHg)
133.2 (16.3) 133.3 (16.8) 123.5 (10.5) 134.8 (16.5) 132.9 (18.8) 0.994 0.907
Diastolic blood pressure
(mmHg)
69.1 (9.1) 68.4 (8.4) 65.3 (4.6) 68.1 (4.8) 68.0 (4.6) 0.348 0.422
Serum total cholesterol
(mmol/l)
4.3 (0.9) 4.5 (0.9) 4.3 (0.8) 4.5 (0.9) 4.4 (0.9) 0.020 0.064
Serum HDL-cholesterol
(mmol/l)
1.3 (0.4) 1.4 (0.4) 1.2 (0.3) 1.4 (0.4) 1.5 (0.5) !0.001 0.005 (0.002)
Liver variables
Severe hepatic steatosis
on ultrasound, n (%)
445 (55.6) 88 (63.3) 12 (85.7) 54 (60.7) 22 (61.1) 0.091 0.181
d
Serum ALT (U/l) 43.6 (14.6) 41.3 (12.6) 46.2 (13.4) 40.7 (12.6) 40.9 (12.1) 0.070 0.153
Serum AST (U/l) 31.4 (10.4) 28.4 (8.4) 31.8 (11.7) 28.3 (8.3) 27.5 (6.8) 0.001 0.001 (0.018)
Serum GGT (U/l) 2.9 (2.4–3.4) 2.9 (2.5–3.5) 2.9 (2.3–3.4) 2.9 (2.4–3.5) 3.0 (2.6–3.5) 0.601 0.658
Serum bilirubin (mmol/l) 10.2 (5.0) 9.4 (4.4) 9.3 (3.8) 9.3 (4.2) 9.6 (5.0) 0.063 0.181
Serum albumin (g/l) 44.9 (3.2) 44.1 (3.7) 44.3 (4.4) 44.4 (3.5) 43.3 (4.2) 0.013 0.020 (0.025)
Inﬂammatory variables in blood
IL6 (pg/ml) 2.8 (1.9–4.3) 3.2 (2.2–5.4) 2.8 (1.8–4.6) 3.1 (2.2–5.0) 3.7 (2.3–9.4) 0.002 0.006 (!0.001)
C-reactive protein (mg/l) 1.8 (0.8–3.9) 3.0 (1.3–6.6) 2.2 (1.3–3.1) 3.2 (1.2–6.7) 3.3 (1.4–7.7) !0.001 !0.001 (0.001)
TNFa (pg/ml) 1.1 (0.7–1.6) 1.2 (0.7–1.7) 1.2 (0.6–1.6) 1.1 (0.7–1.6) 1.4 (1.0–1.8) 0.787 0.500
Fibrinogen (mg/l) 3.6 (0.7) 3.8 (0.8) 3.5 (1.1) 3.8 (0.8) 3.9 (0.7) 0.064 0.143
White cell count (!10
9/l) 7.1 (2.3) 7.8 (2.3) 8.6 (2.4) 7.5 (1.9) 8.5 (2.8) !0.001 0.001 (0.024)
Neutrophil count (!10
9/l) 4.4 (1.5) 5.1 (1.8) 5.3 (1.9) 4.8 (1.6) 5.6 (2.1) !0.001 !0.001 (!0.001)
Anthropometric variables
Weight (kg) 86.2 (15.9) 87.6 (17.3) 86.3 (16.0) 83.3 (14.2) 88.8 (18.3) 0.327 0.112
BMI (kg/m
2) 31.3 (5.6) 32.3 (6.0) 31.1 (4.1) 32.7 (6.6) 31.5 (4.9) 0.045 0.100
Waist (cm)
Males 107.7 (11.9) 111.7 (12.5) 112.3 (8.1) 112.1 (13.6) 110.5 (10.9) 0.009 0.002 (0.242)
Females 105.0 (13.0) 108.0 (14.3) 103.7 (13.7) 109.0 (15.2) 107.0 (12.3) 0.055 0.070 (0.128)
Hip (cm)
Males 107.6 (9.5) 110.0 (9.9) 109.3 (11.5) 109.8 (10.5) 110.8 (7.7) 0.054 0.020 (0.096)
Females 113.9 (13.0) 114.7 (15.1) 111.8 (13.4) 116.3 (16.8) 111.8 (10.2) 0.577 0.725
Waist/hip
Males 1.001 (0.061) 1.015 (0.058) 1.031 (0.040) 1.019 (0.064) 0.996 (0.043) 0.046 0.031
Females 0.924 (0.070) 0.944 (0.071) 0.928 (0.075) 0.941 (0.065) 0.958 (0.083) 0.015 0.010 (0.005)
GCs, glucocorticoids; ALT, alanine aminotransferase; AST, aspartate transaminase; GGT, g-glutamyl transpeptidase; IL6, interleukin 6; TNFa, tumour
necrosis factor a.
aT-test and c
2 test were used to compare continuous or categorical variables between treatment groups (GCs vs non-GCs).
bAnalysis of covariance (ANCOVA) was used to compare GCs vs non-GCs groups while adjusting for covariates. All analyses have been adjusted for gender,
age and duration of diabetes. Additional adjustments have been performed: i) glucose and HbA1c% also adjusted for anti-diabetic treatment and BMI; ii)
systolic and diastolic blood pressure also adjusted for anti-hypertensive treatment and BMI; iii) total cholesterol and HDL-cholesterol also adjusted for lipid-
lowering treatment; iv) liver variables and inﬂammatory variables also adjusted for BMI; and v) BMI and anthropometric variables also adjusted for smoking.
cWhen primary ANCOVA analysis was signiﬁcant, a secondary trend analysis was performed using the linear polynomial contrast of ANCOVA among the four
treatment groups: i) not taking GCs, ii) topical, iii) inhaled and iv) oral/i.m.
dLogistic regression was used to explore the relationship between glucocorticoid treatment and hepatic steatosis while adjusting for covariates (age, gender,
duration of diabetes and BMI).
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and serum levels of bilirubin, alanine transferase (ALT)
and aspartate transferase (AST) tended to be lower in
these subjects.
Glucocorticoid treatment and mood and
cognitive function
Table 3 shows that subjects treated with glucocorticoids
had higher scores on both the anxiety and depression
scales of the HADS. Risk of anxiety was similar in males
and females, but there was a gender difference in the
risk of depression, with women taking glucocorticoid
therapy having higher depression scores. Using a cut-off
score on the HADS-depression scale of 8, a valid cut-off
in screening for depression (18),w o m e nt a k i n g
glucocorticoid therapy were twice as likely to report
symptoms of depression (OR 2.35 (1.35–4.5),
PZ0.005) compared with women not taking gluco-
corticoid therapy. This association was not seen in
men (OR 0.83 (0.32–2.18), PZ0.699).
Table 3 also shows that in univariate analyses, there
were no differences between subjects taking or not
taking glucocorticoid therapy in overall cognitive ability
(g) or in the speciﬁc cognitive domains tested. However,
in the multivariate analyses, we found a signiﬁcant
relationship between glucocorticoid treatment and
a poorer performance on the TMT with a signiﬁcant
interaction between ABI and glucocorticoid treatment.
No signiﬁcant interactions were found in analyses
exploring other cognitive domains or mood status. In
the stratiﬁed analysis by ABI (Table 4), glucocorticoid
therapy was signiﬁcantly associated with poorer
cognitive function on the trail-making test, with trends
for poorer overall cognitive ability (g) and for poorer
matrix reasoning and letter number sequencing scores,
in subjects with lower ABI (!0.8) (nZ147). Cognitive
function was not related to glucocorticoid therapy in
those with normal ABI.
Dose–response relationships with gluco-
corticoid treatment
For variables for which there was a difference between
the glucocorticoid-treated and -untreated groups, we
explored dose–response relationships by comparing
groups receiving topical, inhaled or systemic therapy.
In general, differences in the glucocorticoid-treated
group were more obvious among those receiving
systemic therapy, although differences between the
topical and inhaled treatment groups were less
consistent, for example with regard to white blood
cell and neutrophil counts and to waist:hip ratio
in men.
Table 3 Mood and cognitive measures. Data are mean (S.D.) or median (interquartile range).
GCs vs non-GCs
Not taking
GCs (nZ904)
Taking GCs
(nZ162)
Topical
(nZ15)
Inhaled
(nZ107)
Oral/i.m.
(nZ40)
P
value
a
Adjusted P value
b
(adjusted P value
for trend
c)
Anxiety and depressive symptoms
HADS – anxiety score 5 (3–8) 6.5 (3–9) 7 (3–9) 7 (3–9) 5 (3–8.8) 0.005 0.027 (0.131)
HADS – depression score 3 (1–5) 4 (2–6) 4 (2–5) 4 (2–7) 4 (2–6) 0.017 0.076
Mill Hill Vocabulary Scale 31.0 (5.2) 30.8 (5.4) 32.5 (5.6) 30.2 (5.8) 31.7 (3.7) 0.640 0.625
Cognitive assessment
Mini-Mental State Examination
Score
28.3 (1.9) 28.3 (1.9) 28.7 (1.5) 28.1 (2.1) 28.7 (1.3) 0.967 0.986
Matrix Reasoning Score 13.0 (5.3) 12.2 (5.3) 15.5 (4.8) 11.8 (5.3) 12.2 (5.0) 0.132 0.160
Digit Symbol Test Score 49.4 (15.0) 48.2 (13.6) 53.3 (10.2) 48.1 (14.0) 46.4 (13.3) 0.335 0.285
Borkowski verbal ﬂuency
test score
36.8 (12.8) 37.7 (12.8) 41.1 (11.6) 37.7 (13.2) 36.6 (12.2) 0.387 0.075
Letter number sequencing
score
9.7 (2.7) 9.6 (2.8) 10.9 (1.8) 9.5 (2.9) 9.6 (2.8) 0.881 0.720
Trail-making test (s) 103 (80–138) 107.5 (83–139) 100 (60–139) 108.5 (83–135) 112 (84–154) 0.333 0.025
d (0.045)
Faces 65.8 (7.9) 65.8 (8.2) 67.7 (10.0) 65.6 (8.2) 65.8 (7.8) 0.988 0.957
Logical memory 25.1 (8.2) 26.1 (7.9) 28.9 (6.5) 25.9 (8.3) 25.7 (7.1) 0.145 0.106
G 0.01 (0.99) K0.04 (1.04) 0.54 (0.85) K0.06 (1.06) K0.18 (1.02) 0.673 0.972
GCs, glucocorticoids; HADS, Hospital Anxiety and Depression Scale; G, general cognitive ability factor; ABI, ankle–brachial index.
aT-test was used to compare mood and cognition scores between treatment groups (GCs vs non-GCs).
bAnalysis of covariance was used to adjust for covariates. Mood scores were adjusted for age, gender, education level, duration of diabetes, cerebrovascular
disease (stroke or TIA), ABI and antidepressant treatment. Cognitive measures were adjusted for age, gender, education level, duration of diabetes,
cerebrovascular disease (stroke or TIA), ABI, Mill Hill Vocabulary Scale, HADS depression and anxiety scores.
cWhen primary ANCOVA analysis was signiﬁcant, a secondary trend analysis was performed using the linear polynomial contrast of ANCOVA among the four
treatment groups: i) not taking GCs, ii) topical, iii) inhaled and iv) oral/i.m.
dA signiﬁcantinteraction term betweenglucocorticoid treatment and ABI (PZ0.031) was included in this analysis. Other covariates signiﬁcantly associated with
the Trail-making test were age, duration of diabetes, cerebrovascular disease, Mill Hill Vocabulary Scale and HADS depression score.
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In this cohort study of elderly people with type 2
diabetes, glucocorticoid treatment was widely used,
with nearly 14% of participants taking glucocorticoid
therapy by some route. Treatment with glucocorticoids
was associated with an adverse metabolic proﬁle with
increased obesity, poorer glycaemic control and higher
total cholesterol (albeit also with higher atheroprotec-
tive HDL-cholesterol). Glucocorticoid therapy was also
associated with lower mood, especially in women, and
increased anxiety. Moreover, we found evidence that
glucocorticoid therapy is independently associated with
impaired cognitive function in the trail-making test
among patients with subclinical atherosclerosis.
Our ﬁndings add to the literature that glucocorticoid
treatment is associated with adverse cardiovascular risk
among the general population (4, 5, 22). People with
type 2 diabetes are at high cardiovascular risk (9), and
the majority of patients were receiving secondary
preventative treatment with statins and/or blood
pressure-lowering agents (15). Levels of HbA1c, choles-
terol and blood pressure were within, or approaching,
recommended targets (Management of Diabetes. SIGN
Guideline. 2011 www.sign.ac.uk). Despite this, we still
found glucocorticoid treatment was associated with
poorer glycaemic control and higher total cholesterol,
although the magnitude of difference between groups
was small. As expected, glucocorticoid therapy was
associated with increased obesity and particularly with
central obesityas seen in Cushing’ssyndrome. However,
the ﬁndingof lower levels of liver function tests in people
taking glucocorticoids and relatively weak association
with hepatic steatosis was surprising, as patients with
spontaneous Cushing’s syndrome are reported to have
a high prevalence of hepatic steatosis (23).I tm a yb e
relevant that the liver scans were undertaken 1 year
later than the initial visit at which glucocorticoid
exposure was assessed. However, when we reanalysed
the data using glucocorticoid use within the 6 months
before the liver scans (data not shown), the ﬁndings
were no different.
Glucocorticoid excess is also a well-known cause of
mood disorders, consistent with our ﬁnding that people
treated with glucocorticoids had lower mood and were
more anxious. The magnitude of these differences may
be clinically signiﬁcant; in particular, women taking
glucocorticoid therapy were twice as likely to report
symptoms of depression compared with those not taking
glucocorticoids. Although women are at greater risk of
depression than men, and this may account, in part, for
a greater risk of depression with glucocorticoid
treatment, there is no consistency in the literature
as to whether females are more vulnerable to depres-
sive symptoms in association with glucocorticoid
therapy (6). Symptoms of depression and anxiety are
common in people with diabetes (10) and are associated
with poorer glycaemic and metabolic control (24).O u r
ﬁndings suggest that treatment with glucocorticoids
is associated with symptoms of depression and anxiety
in people with type 2 diabetes.
People with Cushing’s syndrome have poorer memory
(8),a n dar e c e n ts t u d yh a ss h o w nad o s e - d e p e n d e n t
inhibitory effect of glucocorticoids on emotional
information processing in healthy volunteers (25).H e r e ,
we have found some evidence that glucocorticoid
treatment was associated with poorer cognitive per-
formance, mainly in processing speed. This is the ﬁrst
cognitive domain to show a decline with ageing, show
large declines, and is an early predictor of dementia (26).
Wehavepreviouslyshownpoorerfunctioningonthistest
in association with higher endogenous cortisol levels in
people with type 2 diabetes (11). In the latter study, we
have also reported an interaction between circulating
cortisollevelsandsubclinicalatherosclerosis,asmeasured
Table 4 Mood and cognitive measures: stratiﬁed analysis by ABI. Data are mean (S.D.) or median (interquartile range).
Low ABI (!0.8) (nZ147) Normal ABI (R0.8) (nZ912)
Not taking GCs
(nZ126)
Taking GCs
(nZ21) P value
a
Not taking GCs
(nZ772)
Taking GCs
(nZ140) P value
a
Anxiety and depressive symptoms
HADS – anxiety score 5 (3–8) 8 (4–10) 0.032 5 (3–8) 6 (3–9) 0.077
HADS – depression score 4 (2–6) 6 (3.5–8) 0.023 3 (1–5) 4 (2–6) 0.030
Mill Hill Vocabulary Scale 30.2 (5.0) 27.5 (5.4) 0.081 31.1 (5.3) 31.1 (5.3) 0.991
Cognitive assessment
Mini-Mental State Examination Score 27.8 (2.6) 27.0 (3.0) 0.166 28.4 (1.7) 28.5 (1.6) 0.466
Matrix Reasoning Score 12.0 (5.2) 10.1 (5.0) 0.136 13.1 (5.3) 12.5 (5.2) 0.923
Digit Symbol Test Score 45.2 (14.5) 41.3 (14.8) 0.261 50.1 (15.0) 49.1 (13.1) 0.457
Borkowski Verbal Fluency Test Score 36.3 (13.2) 34.4 (14.1) 0.542 36.7 (12.7) 38.0 (12.4) 0.260
Letter Number Sequencing Score 9.5 (3.0) 8.2 (3.0) 0.092 9.7 (2.7) 9.9 (2.7) 0.548
Trail-making test (s) 107 (84.5–135) 133 (114.5–133) 0.002 103 (80–139) 106 (81–135.5) 0.870
Faces 64.7 (7.7) 64.9 (9.0) 0.931 66.0 (7.8) 66.0 (8.2) 0.999
Logical memory 24.3 (8.2) 26.3 (9.0) 0.329 25.2 (8.2) 26.0 (7.7) 0.265
G K0.19 (0.93) K0.57 (1.12) 0.110 0.03 (1.0) 0.04 (1.01) 0.955
ABI, ankle–brachial pressure index; GCs, glucocorticoids; HADS, Hospital Anxiety and Depression Scale; G, general cognitive ability factor.
aT-test was used to compare mood and cognition scores between treatment groups (GCs vs non-GCs).
866 R M Reynolds and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
www.eje-online.orgby ABI, in predicting cognitive dysfunction in patients
with type 2 diabetes (11). People with subclinical
atherosclerosis may be more susceptible to the detri-
mentaleffectsofglucocorticoidsonhippocampalfunction
(27). We have found support for this inthe currentstudy,
as measurable cognitive dysfunction was restricted to
patients with low ABI, particularly in the trail-making
test,whichisanassessmentofmentalﬂexibility.However,
there was a small number of patients in this group
(nZ21), and the lack of an association between
glucocorticoid exposure and cognitive function in the
whole cohort suggests that, by contrast with the effect of
diabetes per se, any inﬂuence of additional glucocorticoid
therapy on cognitive function is of minor clinical
signiﬁcance.
Given the observational study design, it is impossible
to avoid potential confounding by indication. The
higher levels of inﬂammatory indices in the blood are
consistent with underlying inﬂammatory disease for
which the patients are receiving glucocorticoid therapy,
and it is possible that the underlying disease process is
responsible for the association of glucocorticoid therapy
with metabolic variables and mood. It was not possible
to investigate the consistency of associations with
glucocorticoid therapy in different disease indications
because of the small number of patients available who
were not being treated for obstructive pulmonary
disease. However, it is unlikely that confounding by
indication accounts for all the associations with
glucocorticoid therapy observed here; for example, in
patients with obstructive pulmonary disease, one would
anticipate reduced rather than increased body fat. We
also repeated all analyses to test whether inclusion of
inﬂammatory markers (IL6, CRP) moderated the
ﬁndings between glucocorticoid therapy and outcomes
(data not shown) and found no change in the results.
The inference that glucocorticoid therapy contributes
directly to adverse metabolic outcomes is further
supported by the persistence of relationships after
adjustment for smoking and by the dose–response
relationships with glucocorticoid exposure, although
this was less apparent for symptoms of depression and
anxiety.
The strengths of this study include the large sample
size and the application of a battery of seven
psychometric tests, which provides a relatively compre-
hensive and validated assessment of cognitive domains
and mood states. There was also detailed phenotyping
for potential confounding or mediating factors. The
study population had a veriﬁed clinical diagnosis of
type 2 diabetes and was representative of the wider
type 2 diabetic population (elderly, community-dwelling
men and women with the full spectrum of severity of
type 2 diabetes, from diet-controlled to insulin-treated).
Many large-scale studies on people with diabetes are
restricted to those attending hospital clinics and biased
towards the more severe end of the spectrum of diabetes.
Although the use of multiple tests raises the possibility
of multiple testing with associated false-positive results,
this possibility was acknowledged by both general
cognitive factors and the individual tests. The advan-
tages of having detailed information on such a wide
range of phenotypes outweigh the remaining statistical
concerns. We asked all subjects about glucocorticoid
treatment, including topical and inhaled gluco-
corticoids, as these have systemic effects. However,
estimation of glucocorticoid exposure is not straightfor-
ward as glucocorticoid treatment for chronic disease is
typically intermittent over many years. We veriﬁed that
all subjects had received at least one prescription for
glucocorticoid therapy during the 3 months before the
study by manual checking of primary care prescription
records, but we were unable to obtain data over a longer
period to provide an estimate of cumulative glucocorti-
coid exposure. Unfortunately, data were not available
on other important indices of the adverse effects of
glucocorticoids, such as bone density.
In conclusion, a large number of our elderly subjects
with type 2 diabetes were prescribed glucocorticoid
therapy, and this was associated with some adverse
indices of metabolic and brain function. A direct causal
link cannot be proved due to the cross-sectional design
of our study and prospective studies are needed.
Nevertheless, clinicians should be aware that in
addition to encouraging weight gain and worsening
glycaemic control, glucocorticoid treatment has
potential negative effects on cardiovascular risk and
cognition in people with type 2 diabetes, although
arguably the magnitude of these effects was surprisingly
small. Perhaps more importantly, the risk of mood
disturbance in patients receiving glucocorticoids
deserves closer attention when deciding whether to
initiate or continue glucocorticoid therapy.
Declaration of interest
The authors declare that there is no conﬂict of interest that could be
perceived as prejudicing the impartiality of the research reported.
Funding
This study was supported by a grant from the Medical Research
Council (2006–2011).
Author contribution statement
R M Reynolds designed and carried out the study, interpreted the data
and wrote the manuscript. R M Reynolds is guarantor for the
manuscript. J Labad carried out the statistical analysis, interpreted the
data and contributed to writing the manuscript. AV Sears veriﬁed and
collected the data and approved the ﬁnal version of the manuscript.
R M Williamson carried out the liver ‘sub-study’ and edited the
manuscript. M W J Strachan designed and carried out the study and
approved the ﬁnal version of the manuscript. I J Deary designed the
study, interpreted the data and contributed to the writing of the
manuscript. G D O Lowe carried out the biochemical analyses and
edited the manuscript. J F Price designed and carried out the studyand
edited the manuscript. B RWalker designed the study, interpreted the
data and contributed to the writing of the manuscript.
Glucocorticoid treatment in type 2 diabetes 867 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
www.eje-online.orgAcknowledgements
We acknowledge the support of the British Heart Foundation. The liver
‘sub-study’ was funded by Pﬁzer Ltd. All authors thank their
co-investigators and collaborators and all the participants and staff of
theEdinburghType2DiabetesStudyandthestaffattheWellcomeTrust
Clinical Research Facility where the study was performed. J Labad
received an Intensiﬁcation of Research Activity grant (Programme
13SNS-INT 11/323) from the Instituto de Salud Carlos III (Spain).
References
1 van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B &
Cooper C. Use of oral corticosteroids in the United Kingdom.
Quarterly Journal of Medicine 2000 93 105–111. (doi:10.1093/
qjmed/93.2.105)
2 Andrews RC & Walker BR. Glucocorticoids and insulin resistance:
old hormones, new targets. Clinical Science 1999 96 513–523.
(doi:10.1042/CS19980388)
3 Delaunay F, Khan A, Cintra A, Davani B, Ling Z-C, Andersson A,
Ostenson CG, Gustafsson J, Efendic S & Okret S. Pancreatic
beta cells are important targets for the diabetogenic effects
of glucocorticoids. Journal of Clinical Investigation 1997 100
2094–2098. (doi:10.1172/JCI119743)
4 Souverain PC, Berard A, van Staa TP, Cooper C, Leufkens HGM &
Walker BR. Use of oral glucocorticoids and risk of cardiovascular
and cerebrovascular disease in a population-based case–control
study. Heart 2004 90 859–865. (doi:10.1136/hrt.2003.020180)
5 Wei L, MacDonald TM & Walker BR. Taking glucocorticoids by
prescription is associated with subsequent cardiovascular disease.
Annals of Internal Medicine 2004 141 764–770.
6 Brown ES. Effects of glucocorticoids on mood, memory, and the
hippocampus. Treatment and preventive therapy. Annals of the
New York Academy of Sciences 2009 1179 41–55. (doi:10.1111/j.
1749-6632.2009.04981.x)
7 Pariante CM. The glucocorticoid receptor: part of the solution
or part of the problem? Journal of Psychopharmacology 2006 20
79–84. (doi:10.1177/1359786806066063)
8 Starkman MN, Giordani B, Berent S, Schork MA & Schteingart DE.
Elevated cortisol levels in Cushing’s disease are associated with
cognitive decrements. Psychosomatic Medicine 2001 63 985–993.
9 Haffner SM, Lehto S, Ronnemaa T, Pyorala K & Laakso M.
Mortality from coronary heart disease in subjects with type 2
diabetes and in nondiabetic subjects with and without prior
myocardial infarction. New England Journal of Medicine 1998 339
229–234. (doi:10.1056/NEJM199807233390404)
10 Labad J, PriceJF, StrachanMW, Fowkes FG,DingJ, Deary IJ, Lee AJ,
Frier BM, Seckl JR, Walker BR & Reynolds RM & Edinburgh Type 2
Diabetes study investigators. Symptoms of depression but not
anxiety are associated with central obesity and cardiovascular
disease in people with type 2 diabetes: the Edinburgh Type 2
Diabetes Study. Diabetologia 2010 53 467–471. (doi:10.1007/
s00125-009-1628-9)
11 Reynolds RM, Strachan MW, Labad J, Lee AJ, Frier BM, Fowkes FG,
Mitchell R, Seckl JR, Deary IJ, Walker BR & Price JF & Edinburgh
Type 2 Diabetes study investigators. Morning cortisol levels and
cognitive abilities in people with type 2 diabetes: the Edinburgh
Type 2 Diabetes Study. Diabetes Care 2010 33 714–720.
(doi:10.2337/dc09-1796)
12 Blackburn D, Hux J & Mamdani M. Quantiﬁcation of the
risk of corticosteroid-induced diabetes mellitus among the elderly.
Journal of General Internal Medicine 2002 17 717–720.
(doi:10.1046/j.1525-1497.2002.10649.x)
13 Gulliford MC, Charlton J & Latinovic R. Risk of diabetes associated
with prescribed glucocorticoids in a large population. Diabetes Care
2006 29 2728–2729. (doi:10.2337/dc06-1499)
14 Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H & Avorn J.
Glucocorticoids and the risk for initiation of hypoglycemic therapy.
Archives of Internal Medicine 1994 154 97–101. (doi:10.1001/
archinte.1994.00420010131015)
15 Price JF, Reynolds RM, Mitchell RJ, Williamson RM, Fowkes FG,
Deary IJ, Lee AJ, Frier BM, Hayes PC & Strachan MW. The
Edinburgh Type 2 Diabetes Study: study protocol. BMC Endocrine
Disorders 2008 8 18. (doi:10.1186/1472-6823-8-18)
16 Rose GA. The diagnosis of ischaemic heart pain and intermittent
claudication in ﬁeld surveys. Bulletin of the World Health
Organisation 1962 27 645–658.
17 Gale CR, Allerhand M, Sayer AA, Cooper C, Dennison EM,
Starr JM, Ben-Shlomo Y, Gallacher JE, Kuh D & Deary IJ &
HALCyon Study Team. The structure of the Hospital Anxiety and
Depression Scale in four cohorts of community-based, healthy
older people: the HALCyon program. International Psychogeriatrics
2010 22 559–571. (doi:10.1017/S1041610210000256)
18 Bjelland I, Dahl AA, Haug TT & Neckelmann D. The validity of
the Hospital Anxiety and Depression Scale. An updated litera-
ture review. Journal of Psychosomatic Research 2002 52 69–77.
(doi:10.1016/S0022-3999(01)00296-3)
19 Reynolds RM, Labad J, Strachan MW, Braun A, Fowkes FG, Lee AJ,
Frier BM, Seckl JR, Walker BR & Price JF & Edinburgh Type 2
Diabetes Study (ET2DS) Investigators. Elevated fasting plasma
cortisol is associated with ischemic heart disease and its risk
factors in people with type 2 diabetes: the Edinburgh Type 2
Diabetes Study. Journal of Clinical Endocrinology and Metabolism
2010 95 1602–1608. (doi:10.1210/jc.2009-2112)
20 Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC,
FrierBM, VanLook LA,JohnstonGI, ReynoldsRM & Strachan MW
& Edinburgh Type 2 Diabetes study investigators. Prevalence of
and risk factors for hepatic steatosis and nonalcoholic fatty liver
disease in people with type 2 diabetes: the Edinburgh Type 2
Diabetes Study. Diabetes Care 2011 34 1139–1144. (doi:10.2337/
dc10-2229)
21 Williamson RM, Perry E, Glancy S, Marshall I, Gray C, Nee LD,
Hayes PC, Forbes S, Frier BM, Johnston GI, Lee AJ, Reynolds RM,
Price JF, MW Strachan & Edinburgh Type 2 Diabetes study
investigators. The use of ultrasound to diagnose hepatic steatosis
in type 2 diabetes: intra- and interobserver variability and com-
parison with magnetic resonance spectroscopy. Clinical Radiology
2011 66 434–439. (doi:10.1016/j.crad.2010.09.021)
22 Walker BR. Glucocorticoids and cardiovascular disease. European
Journal of Endocrinology 2007 157 545–559. (doi:10.1530/EJE-
07-0455)
23 Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP,
Besser GM, Grossman AB & Reznek RH. Hepatic steatosis
in Cushing’s syndrome: a radiological assessment using
computed tomography. European Journal of Endocrinology 2003
149 543–548. (doi:10.1530/eje.0.1490543)
24 Katon W, Von Korff M, Ciechanowski P, Russo J, Lin E, Simon G,
Ludman E, Walker E, Bush T & Young B. Behavioral and
clinical factors associated with depression among individuals with
diabetes.DiabetesCare200427914–920.(doi:10.2337/diacare.27.
4.914)
25 Taylor VA, Ellenbogen MA, Washburn D & Joober R. The effects
of glucocorticoids on the inhibition of emotional information:
a dose–response study. Biological Psychology 2011 86 17–25.
(doi:10.1016/j.biopsycho.2010.10.001)
26 Finkel D, Reynolds CA, McArdle JJ & Pedersen NL. Age changes in
processing speed as a leading indicator of cognitive aging.
Psychology and Aging 2007 22 558–568. (doi:10.1037/0882-
7974.22.3.558)
27 Stranahan AM, Arumugam TV, Cutler RG, Lee K, Egan JM &
Mattson MP. Diabetes impairs hippocampal function through
glucocorticoid-mediated effects on new and mature neurons.
Nature Neuroscience 2008 11 309–317. (doi:10.1038/nn2055)
Received 16 January 2012
Revised version received 25 February 2012
Accepted 9 March 2012
868 R M Reynolds and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
www.eje-online.org